CZ20011186A3 - Stabilizovaný farmaceutický prostředek - Google Patents

Stabilizovaný farmaceutický prostředek

Info

Publication number
CZ20011186A3
CZ20011186A3 CZ20011186A CZ20011186A CZ20011186A3 CZ 20011186 A3 CZ20011186 A3 CZ 20011186A3 CZ 20011186 A CZ20011186 A CZ 20011186A CZ 20011186 A CZ20011186 A CZ 20011186A CZ 20011186 A3 CZ20011186 A3 CZ 20011186A3
Authority
CZ
Czechia
Prior art keywords
pharmaceutical preparation
stabilized pharmaceutical
stabilized
preparation
pharmaceutical
Prior art date
Application number
CZ20011186A
Other languages
English (en)
Other versions
CZ295720B6 (cs
Inventor
Seiji Sawai
Akihiro Kasai
Kazumi Otomo
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ20011186(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of CZ20011186A3 publication Critical patent/CZ20011186A3/cs
Publication of CZ295720B6 publication Critical patent/CZ295720B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CZ20011186A 1999-07-01 2000-06-29 Stabilizovaný farmaceutický prostředek a způsob jeho výroby CZ295720B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01

Publications (2)

Publication Number Publication Date
CZ20011186A3 true CZ20011186A3 (cs) 2001-09-12
CZ295720B6 CZ295720B6 (cs) 2005-10-12

Family

ID=16210881

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011186A CZ295720B6 (cs) 1999-07-01 2000-06-29 Stabilizovaný farmaceutický prostředek a způsob jeho výroby

Country Status (28)

Country Link
US (2) US6774104B1 (cs)
EP (1) EP1107777B1 (cs)
JP (2) JP3381722B2 (cs)
KR (1) KR100454784B1 (cs)
CN (2) CN100352495C (cs)
AR (1) AR024634A1 (cs)
AT (1) ATE280583T1 (cs)
AU (1) AU752265B2 (cs)
BR (2) BRPI0006823B8 (cs)
CA (1) CA2341568C (cs)
CZ (1) CZ295720B6 (cs)
DE (1) DE60015279T2 (cs)
ES (1) ES2225161T3 (cs)
HK (1) HK1040057B (cs)
HU (1) HU229089B1 (cs)
ID (1) ID29468A (cs)
IL (2) IL141455A0 (cs)
MX (1) MXPA01000601A (cs)
NO (1) NO330353B1 (cs)
NZ (1) NZ510290A (cs)
OA (1) OA11601A (cs)
PL (1) PL200141B1 (cs)
PT (1) PT1107777E (cs)
RU (1) RU2251411C2 (cs)
TR (1) TR200100609T1 (cs)
TW (1) TWI233805B (cs)
WO (1) WO2001002002A1 (cs)
ZA (1) ZA200101589B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
ATE528003T1 (de) 2002-07-31 2011-10-15 Senju Pharma Co Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen
DK1565201T3 (en) * 2002-11-18 2019-02-25 Vicuron Pharmaceuticals Llc METHODS OF ADMINISTRATING DALBAVANCIN TO TREAT Bacterial Infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
JPWO2005084679A1 (ja) * 2004-03-04 2007-11-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法
EP1751150A2 (en) * 2004-05-19 2007-02-14 Neurosearch A/S Novel azabicyclic aryl derivatives
CN101107013A (zh) * 2004-11-22 2008-01-16 阿纳迪斯有限公司 生物活性组合物
KR101307999B1 (ko) 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
EP1921453A4 (en) * 2005-07-20 2008-12-31 Kyowa Medex Co Ltd PROCESS FOR STABILIZING PEPTIDE CONTAINED IN A BIOLOGICAL SAMPLE
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
AP2014008084A0 (en) * 2012-05-22 2014-11-30 Paion Uk Ltd Compositions comprising shortacting benzodiazepines
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
MX387913B (es) 2013-03-15 2025-03-19 Merck Sharp & Dohme Llc Composiciones antibioticas de ceftolozano
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
RU2726416C2 (ru) * 2013-06-05 2020-07-14 Ти Юниверсити Оф Бритиш Коламбиа Антифиброгенные соединения, способы и их применение
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
US20170190742A1 (en) * 2014-05-29 2017-07-06 Shanghai Techwell Biopharmaceutical Co., Ltd. Composition of cyclic peptide compound, preparation method for same, and uses thereof
MY190283A (en) * 2014-12-05 2022-04-12 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
PL3240529T3 (pl) * 2014-12-31 2022-05-02 Galenicum Health S.L.U. Stabilne kompozycje farmaceutyczne zawierające mykafunginę
EP3058958B1 (en) 2015-02-23 2018-09-19 Selectchemie AG Anidulafungin composition
PT3554474T (pt) 2016-12-16 2024-02-12 Baxter Healthcare Sa Composições de micafungina
US11185527B2 (en) 2017-06-26 2021-11-30 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
RU2095081C1 (ru) * 1991-12-13 1997-11-10 Акционерное общество "Биофа" Фармацевтическая композиция антивирусного действия
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
IL109615A (en) * 1993-05-17 2000-12-06 Fujisawa Pharmaceutical Co Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
DE69529172T2 (de) 1994-10-07 2003-04-17 Fujisawa Pharmaceutical Co., Ltd. Zyklische hexapeptide mit antibiotischer aktivität
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
JP3123078B2 (ja) * 1996-03-08 2001-01-09 藤沢薬品工業株式会社 環状リポペプチド物質の脱アシル化法
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
EP1156782B1 (en) * 1999-03-03 2005-05-04 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
EP1156784A1 (en) * 1999-03-03 2001-11-28 Eli Lilly And Company Processes for making pharmaceutical oral ecb formulations and compositions
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
BRPI0006823B1 (pt) 2020-01-07
CN1315865A (zh) 2001-10-03
PT1107777E (pt) 2005-01-31
EP1107777A1 (en) 2001-06-20
NZ510290A (en) 2003-07-25
AU5572200A (en) 2001-01-22
MXPA01000601A (es) 2002-04-08
ES2225161T3 (es) 2005-03-16
HK1040057A1 (en) 2002-05-24
ATE280583T1 (de) 2004-11-15
JP2003503462A (ja) 2003-01-28
OA11601A (en) 2004-07-30
NO20010893L (no) 2001-04-24
US6774104B1 (en) 2004-08-10
JP2002363097A (ja) 2002-12-18
ID29468A (id) 2001-08-30
TWI233805B (en) 2005-06-11
CN1636591A (zh) 2005-07-13
BRPI0006823B8 (pt) 2021-05-25
CA2341568A1 (en) 2001-01-11
IL141455A (en) 2006-12-31
CA2341568C (en) 2011-10-25
NO20010893D0 (no) 2001-02-22
EP1107777B1 (en) 2004-10-27
US20040157769A1 (en) 2004-08-12
KR100454784B1 (ko) 2004-11-05
IL141455A0 (en) 2002-03-10
HK1080724A1 (zh) 2006-05-04
HU229089B1 (en) 2013-07-29
BR0006823A (pt) 2001-06-05
DE60015279D1 (de) 2004-12-02
PL200141B1 (pl) 2008-12-31
HUP0103740A2 (hu) 2002-02-28
WO2001002002A1 (en) 2001-01-11
CN1179748C (zh) 2004-12-15
DE60015279T2 (de) 2005-05-25
JP4691866B2 (ja) 2011-06-01
AR024634A1 (es) 2002-10-16
HK1040057B (zh) 2005-08-05
NO330353B1 (no) 2011-04-04
TR200100609T1 (tr) 2001-07-23
KR20010072903A (ko) 2001-07-31
US7112565B2 (en) 2006-09-26
PL346297A1 (en) 2002-01-28
JP3381722B2 (ja) 2003-03-04
RU2251411C2 (ru) 2005-05-10
HUP0103740A3 (en) 2002-08-28
AU752265B2 (en) 2002-09-12
CZ295720B6 (cs) 2005-10-12
ZA200101589B (en) 2002-09-02
CN100352495C (zh) 2007-12-05

Similar Documents

Publication Publication Date Title
CZ20011186A3 (cs) Stabilizovaný farmaceutický prostředek
CZ20011518A3 (cs) Farmaceutický prostředek
HUP0203585A3 (en) Pharmaceutical combinations
IL145632A0 (en) Pharmaceutical compounds
EG23937A (en) Novel pharmaceutical
GB9916434D0 (en) Pharmaceutical compounds
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
GB9914255D0 (en) Pharmaceutical compounds
GB9909041D0 (en) Novel pharmaceutical
EG23946A (en) Novel pharmaceutical
GB9903784D0 (en) Pharmaceutical compounds
IL146341A0 (en) Pharmaceutical complex
GB9909154D0 (en) Pharmaceutical formulation
GB2373499B (en) Pharmaceutical compounds
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB9926251D0 (en) Pharmaceutical formulation
GB9923933D0 (en) Novel pharmaceutical
HU9902398D0 (en) Pharmaceutical preparation
GB9923934D0 (en) Novel pharmaceutical
GB9926434D0 (en) Pharmaceutical
GB9926437D0 (en) Pharmaceutical
GB9905983D0 (en) Pharmaceutical formulations
GB9903177D0 (en) Pharmaceutical formulations
GB9911826D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20200629